NorthStar Medical Radioisotopes has launched its new radiopharmaceutical Contract Development and Manufacturing (CDMO) facility on its campus in Beloit, WI.
The 52,000-sq-ft facility will provide biopharmaceutical and pharmaceutical companies with development services and dose manufacturing capacity for key imaging and therapeutic radioisotopes, including actinium-225, lutetium-177, copper-64, copper-67, and indium-111, among others, the company said.
The facility’s design adds capacity to the industry and will allow NorthStar to meet increasing demands for medical isotopes while helping customers navigate the complexities of radioisotope research, development, and manufacturing, according to NorthStar.
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
